ACRBP and neoplasm: Numerous studies have depicted abnormal expression of OY-TES-1 in many tumors such as epithelial ovarian cancer [9], colorectal cancer [10], and glioma [11] where its expression is associated with poor patient outcomes, high tumor grades, and malignant characteristics such as tumor cell invasion and metastasis.